Ajanta Pharma FY25 Annual Earnings Summary
4 quarters covered · ₹4,648 Cr revenue · ₹920 Cr PAT · 27.0% average EBITDA margin.
Quarter-by-quarter progression
Management promises made during the year
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q1 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q1 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q1 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q1 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q3 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q3 FY25Risks flagged during the year
Africa anti-malarial business declined ~42% in 9M FY25 due to lower Global Fund procurement; future depends on donor funding, which is uncertain given U.S. policy changes.
Q4 FY25 · highThe US has initiated a Section 232 investigation into pharmaceutical imports, which could lead to tariffs. Management has a directional plan but no clarity on outcome.
Q1 FY25 · mediumAfrica institutional revenue fell 36% YoY due to procurement schedule shifts; management noted this business remains unpredictable.
Q1 FY25 · mediumManagement expects an adverse impact of INR 30 crore in freight costs for FY25 compared to FY24, assuming current rates persist.
Q2 FY25 · mediumFreight costs remain elevated due to Red Sea crisis, with an annual burden of ~INR 30 crore impacting other expenses.
Q2 FY25 · mediumInstitutional business (anti-malarial) remains unpredictable due to reliance on procurement agency schedules and funding.
Q2 FY25 · mediumUS generics growth remains muted at 2% in H1, with limited launches; pricing pressure and competitive landscape could impact future growth.
Q3 FY25 · mediumU.S. generics growth is dependent on new product launches and limited competition; any delays or higher-than-expected price erosion could impact growth.
Q3 FY25 · mediumEntry into gynecology and nephrology in India and CNS in Asia will increase SG&A and personnel costs, potentially pressuring near-term margins.
Q4 FY25 · mediumThe Africa institutional segment declined 53% in Q4 and remains unpredictable due to donor funding uncertainties, including potential USAID cuts.
Q4 FY25 · mediumPersonnel costs rose 21% in FY25 due to MR additions and gratuity policy changes, pressuring EBITDA margins. Normalization expected in FY26 but full-year impact remains.
Q1 FY25 · lowUS generic price erosion remains stable but at high single digits, which could pressure margins if competition intensifies.
What changed through the year
Q1 FY25 · FY25 revenue growth in low teens
Overall revenue expected to grow in low teens, with branded generics mid-teens, US mid-single digit, and Africa institutional degrowth.
Q1 FY25 · EBITDA margin around 29% ±1% for FY25
EBITDA margin expected to remain in the range of 28-30% for the full year, supported by stable gross margins and controlled expenses.
Q1 FY25 · CapEx of INR 175 crore for FY25
Capital expenditure for FY25 estimated at INR 175 crore, including maintenance capex.
Q1 FY25 · US ANDA filings of 8-12 in FY25
Target to file 8-12 ANDAs in the current fiscal year, with launches skewed towards Q3 and Q4.
Q2 FY25 · Branded generics mid-teens growth for FY25
Management expects branded generics (India, Asia, Africa) to grow in mid-teens for the full year, with Asia and Africa growth moderating in H2.
Q2 FY25 · US generics mid-single digit growth for FY25
US generics expected to grow in mid-single digits, with most launches in Q4; 4 ANDA launches planned in H2.
Q2 FY25 · EBITDA margin around 28% ±1% for FY25
Full-year EBITDA margin guided at 28% plus/minus 1%, with quarterly variations due to product mix and forex.
Q2 FY25 · CapEx of INR 200 crore for FY25
Capital expenditure for FY25 estimated at INR 200 crore, including maintenance CapEx; INR 130 crore spent in H1.
Q3 FY25 · EBITDA margin of 28% ±1% for FY25
Management expects EBITDA margin to remain around 28% for the full fiscal year, with quarterly fluctuations of 50-100 bps.
Q3 FY25 · U.S. generics double-digit growth in FY26
Management guided for double-digit growth in U.S. generics next fiscal year, driven by new launches including 2-3 limited competition products.
Q3 FY25 · Capex of ~INR 225 crore for FY25
Capital expenditure for FY25 is estimated at about INR 225 crore, including maintenance capex.
Q3 FY25 · R&D spend at 5% of revenue for FY25
R&D expenses are expected to remain at 5% of total revenue for the fiscal year.
Q4 FY25 · FY26 Revenue Growth: Branded generics low-teens, US generics high-teens
Management expects branded generic business to grow in low teens and US generics in high teens, driven by new product launches and market share gains.
Q4 FY25 · FY26 EBITDA Margin ~28% (similar to FY25)
CFO guided EBITDA margin around 28% plus/minus 1% for FY26, similar to FY25 level, as higher personnel costs offset gross margin improvements.
Q4 FY25 · FY26 Capex ~INR 300 crore
Capital expenditure for FY26 is estimated at around INR 300 crore, including maintenance capex and ongoing projects like the liquid plant at Pithampur.
Q4 FY25 · FY26 ANDA Filings: 10-12 filings
Management expects to file 10-12 ANDAs in FY26, with a robust pipeline and several products in advanced stages.